← Back to Search

Vaccine

mRNA-1345: Exposed for Respiratory Syncytial Virus

N/A
Waitlist Available
Research Sponsored by ModernaTX, Inc.
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 5 years

Summary

The main goal of this observational study is to evaluate the real-world effectiveness of the Moderna mRNA-1345 vaccine for protection against RSV lower respiratory tract disease (RSV-LRTD) and to study additional health and economic outcomes.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 5 years
This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 5 years for reporting.

Treatment Details

Trial Design

2Treatment groups
Experimental Treatment
Group I: mRNA-1345: ExposedExperimental Treatment1 Intervention
Eligible US participants from the mRNA-1345-P301 (P301) study who received the mRNA-1345 vaccine.
Group II: Placebo/Control: ReferentExperimental Treatment1 Intervention
Eligible US participants from the P301 study who received placebo and eligible US-based, matched, unvaccinated RWD participants.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
mRNA-1345
2023
Completed Phase 3
~2560
Placebo
1995
Completed Phase 3
~2670

Find a Location

Who is running the clinical trial?

ModernaTX, Inc.Lead Sponsor
118 Previous Clinical Trials
61,574,229 Total Patients Enrolled
~4649 spots leftby Jun 2026
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top